ICU Medical Inc (STU:IC7)

Q2 2026 ICU Medical, Inc. Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €143 (-1.38%)

Transcript 10-Q8-K

Key Points

Positve

ICU Medical Inc (ICUI) delivered strong Q2 2026 results with total company organic revenue growth of 6%, driven by record sales in both consumables and infusion systems.
Adjusted EBITDA improved to $110 million with a 20% margin, and adjusted EPS rose 13% year-over-year to $2.37, reflecting solid operational execution.
The company raised and narrowed its full-year 2026 adjusted EBITDA guidance to $415-$435 million and adjusted EPS to $8.60-$9.00, signaling confidence in continued momentum.
Free cash flow generation was robust at $62 million in Q2, enabling a $50 million debt repayment and bringing net leverage down to 2.3x, on track to reach the 2x target by year-end.
Significant progress was made on the FDA verification testing for the MedFusion 5000 syringe pump, with an amended submission expected this year, supporting future growth in the infusion systems segment.
The company is realizing benefits from IT systems integration and facility consolidations, contributing to a 1-point improvement in adjusted SG&A as a percentage of revenue and supporting gross margin expansion.

Negative

ICU Medical Inc (ICUI) continues to face headwinds from tariffs, with $8 million in tariff expense recognized in Q2 and an estimated $30-$40 million annual impact, pressuring margins.
Currency fluctuations, particularly in the Costa Rican colón, Mexican peso, and Japanese yen, have negatively impacted results by approximately $60 million over the past four years, with the yen at a 20-year low.
The Vital Care business declined 4% organically in Q2, and while stabilizing, it is expected to be down slightly for the full year due to weak Q1 performance.
The company incurred $21 million in restructuring, integration, and strategic transaction expenses in Q2, including $10 million in non-cash asset write-offs related to facility exits, though cash spend is expected to decline in H2.
The IV Solutions joint venture is expected to contribute only break-even or a small loss for the full year, with typical seasonality and one-time items masking underlying profitability.
Higher logistics costs from elevated diesel prices are pressuring gross margins, partially offsetting benefits from lower tariffs and synergy capture.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ICUI.OQ - ICU Medical, Inc.
Q2 2026 ICU Medical, Inc. Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by, your meeting is about to begin.

Good afternoon everyone, and welcome to today's ICU M second quarter 2026 earnings conference call.

All participants will be in listen-only mode.

After today's presentation, there will be an opportunity to ask questions.

To ask a question at any time, please press 1.

Also, please note that today's event is being recorded.

I'd now like to turn the conference over to John, ICR managing partner, please go ahead.

Good afternoon, everyone.

Thank you for joining us to discuss ICU medical financial results for the second quarter of 2026.

On the call today representing ICU Medical is Vivek Jane, Chief Executive

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.